SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/07/24 Aldeyra Therapeutics, Inc. S-8 POS 3/07/24 1:30K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: S-8 POS Post-Effective Amendment of a Form S-8 HTML 29K Registration
S-8 POS |
As filed with the Securities and Exchange Commission on March 7, 2024
Registration No. 333-275315
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ALDEYRA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 20-1968197 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
131 Hartwell Avenue, Suite 320 |
02421 | |
(Address of Principal Executive Offices) | (Zip Code) |
Aldeyra Therapeutics, Inc. 2023 Equity Incentive Plan
(Full title of plan)
President and Chief Executive Officer
131 Hartwell Avenue, Suite 320
(Name and address of agent for service)
(781) 761-4904
(Telephone number, including area code, of agent for service)
Please send copies of all communications to:
Keith J. Scherer
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
One Marina Park Drive, Suite 900
Telephone: (617) 648-9100
Telecopy: (617) 648-9199
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 is being filed solely to correct exhibit hyperlinks contained in the Registration Statement on Form S-8 (File No. 333-275315) filed with the Securities and Exchange Commission on November 3, 2023.
Item 8. Exhibits.
* | Previously filed with the Registration Statement on Form S-8 (File No. 333-275315) on November 3, 2023. |
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lexington, Commonwealth of Massachusetts, on this 7th day of March, 2024.
ALDEYRA THERAPEUTICS, INC. |
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
President, Chief Executive Officer and Director (Principal Executive Officer) |
March 7, 2024 | |||
* Bruce Greenberg |
Interim Chief Financial Officer (Principal Financial and Accounting Officer) |
March 7, 2024 | ||
* Richard H. Douglas, Ph.D. |
Chairman of the Board of Directors | March 7, 2024 | ||
* Ben Bronstein, M.D. |
Director | March 7, 2024 | ||
* Martin J. Joyce |
Director | March 7, 2024 | ||
* Nancy Miller-Rich |
Director | March 7, 2024 | ||
* Gary Phillips, M.D. |
Director | March 7, 2024 | ||
* Neal Walker, D.O. |
Director | March 7, 2024 |
* By: | /s/ Todd C. Brady, M.D., Ph.D. | |
Todd C. Brady, M.D., Ph.D | ||
Attorney-in-Fact |
This ‘S-8 POS’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / Effective on: | 3/7/24 | 10-K | ||
11/3/23 | 10-Q, S-8 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/03/23 Aldeyra Therapeutics, Inc. S-8 11/03/23 4:118K Donnelley … Solutions/FA 8/03/23 Aldeyra Therapeutics, Inc. 10-Q 6/30/23 66:7.8M Donnelley … Solutions/FA 5/01/20 Aldeyra Therapeutics, Inc. 8-K:5,9 4/30/20 2:124K Donnelley … Solutions/FA 5/07/14 Aldeyra Therapeutics, Inc. 8-K:5,9 5/06/14 3:137K Donnelley … Solutions/FA |